Rationale, design, and experiences from the vanguard phase of the bariatric surgery for the reduction of cardiovascular events (BRAVE) trial.
Jorge A Wong, David Conen, Aristithes Doumouras et al.
✦ AI-curated · Sources linked
In 30 seconds
The BRAVE trial is a multicenter, open-label randomized controlled trial assessing the impact of metabolic/bariatric surgery (MBS) on cardiovascular events in adults with obesity and high-risk cardiovascular disease. The study has randomized 200 participants, revealing a cohort with significant comorbidities, including 82% with hypertension and 45% with diabetes. The primary outcome evaluates a composite of major cardiovascular events.
Key findings
- 200 participants have been randomized in the vanguard phase of the BRAVE trial.
- The cohort has a mean age of 59.8 years and a mean BMI of 44.0 kg/m².
- 82% of participants have hypertension, and 45% have diabetes.
Why it matters
This trial addresses a critical evidence gap regarding the effectiveness of metabolic/bariatric surgery in reducing cardiovascular events among high-risk patients with obesity, potentially influencing treatment strategies in this population.